Higher rate of progression in HIV(–) than in HIV(+) patients after rituximab for HHV8(+) multicentric Castleman disease

Rituximab has revolutionized the treatment of Kaposi sarcoma–associated herpesvirus/human herpesvirus 8–associated multicentric Castleman disease (HHV8(+) MCD), converting a rapidly fatal illness into a relapsing disease. HHV8(+) MCD mainly affects patients with HIV infection but can also be observe...

Descripción completa

Detalles Bibliográficos
Autores principales: Rasmussen, Camille, Gérard, Laurence, Fadlallah, Jehane, Corvilain, Emilie, Galicier, Lionel, Meignin, Véronique, Oksenhendler, Eric, Boutboul, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2023
Materias:
Clinical Trials and Observations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10546345/
https://www.ncbi.nlm.nih.gov/pubmed/37288720
http://dx.doi.org/10.1182/bloodadvances.2023010316

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10546345/
https://www.ncbi.nlm.nih.gov/pubmed/37288720
http://dx.doi.org/10.1182/bloodadvances.2023010316

Ejemplares similares